November 18, 2016 - By Winifred Garcia · 0 Comments
Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) institutional sentiment increased to 5.5 in Q2 2016. Its up 4.30, from 1.2 in 2016Q1. The ratio is positive, as 6 investment managers increased or started new stock positions, while 5 sold and reduced their stakes in Imprimis Pharmaceuticals Inc. The investment managers in our partner’s database now own: 1.66 million shares, down from 2.64 million shares in 2016Q1. Also, the number of investment managers holding Imprimis Pharmaceuticals Inc in their top 10 stock positions was flat from 1 to 1 for the same number . Sold All: 3 Reduced: 2 Increased: 5 New Position: 1.
Imprimis Pharmaceuticals, Inc. is engaged in the development, production and dispensing of compounded pharmaceuticals. The company has a market cap of $26.12 million. The Firm operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. It currently has negative earnings. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases.
About 14,292 shares traded hands. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) has declined 39.70% since April 18, 2016 and is downtrending. It has underperformed by 44.13% the S&P500.
According to Zacks Investment Research, “Imprimis Pharmaceuticals, Inc. is a pharmaceutical company focused on its proprietary ophthalmology and urology drug formulations. Imprimis recently launched its urology business, which includes a patented formulation to address patients suffering from interstitial cystitis.”
Opaleye Management Inc. holds 0.98% of its portfolio in Imprimis Pharmaceuticals Inc for 265,000 shares. Marathon Asset Management Lp owns 833,333 shares or 0.17% of their US portfolio. Moreover, Bard Associates Inc has 0.13% invested in the company for 65,500 shares. The New York-based Berson & Corrado Investment Advisors Llc has invested 0.08% in the stock. Granite Investment Partners Llc, a California-based fund reported 155,190 shares.#img1#
Imprimis Pharmaceuticals, Inc. (Imprimis), incorporated on January 11, 2006, is engaged in the development, production and dispensing of compounded pharmaceuticals. The Firm operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Firm is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Firm also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas, including oncology, autoimmunity, chronic infectious diseases and endocrine and metabolic diseases.
More notable recent Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) news were published by: Finance.Yahoo.com which released: “Imprimis Pharmaceuticals Ranked 12 on Deloitte’s 2016 Technology Fast 500 …” on November 17, 2016, also Prnewswire.com with their article: “Imprimis Pharmaceuticals Strengthens Senior Leadership Team with Key Hires in …” published on August 15, 2016, Prnewswire.com published: “Imprimis Pharmaceuticals Announces Availability of Lower-Cost Option for the …” on October 17, 2016. More interesting news about Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) were released by: Prnewswire.com and their article: “Imprimis Pharmaceuticals Registers its New Jersey Facility with the FDA as an …” published on October 28, 2016 as well as Prnewswire.com‘s news article titled: “Imprimis Pharmaceuticals Announces Preliminary Revenue for Third Quarter 2015” with publication date: October 20, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Winifred Garcia